Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adcetris brentuximab vedotin: Phase II started

Seattle Genetics began an open-label Phase II trial to evaluate 1.2 or 1.8 mg/kg IV Adcetris every 3 weeks for up

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE